HFA Premium Access

Late Breaking Trials I: Focus on acute heart failure

Topic: Acute Heart Failure
Session type: Special Session
Date: 21 May 2016
Time: 14:15 - 15:45

Congress Session

13 presentations in this session

Bi treatment with hydralazine/nitrates versus placebo in africans admitted with acute heart failure (BA-HEF).

Speaker: Professor K. Sliwa (Cape Town, ZA)

Discussion: BA-HEF.


RELAX-REPEAT: a multicentre, prospective, randomised, double-blind study evaluating the safety and tolerability of repeat doses of serelaxin in patients with chronic heart failure.

Speaker: Professor J. Teerlink (San Francisco, US)

Discussion: RELAX-REPEAT.


Positive hemodynamic effects of CXL-1427, a novel nitroxyl prodrug in advanced heart failure patients.

Speaker: Professor V. Mitrovic (Bad Nauheim, DE)

Discussion: CXL-1427.


The trv027 biased ligand of the angiotensin receptor study in acute heart failure (BLAST-AHF) trial: a phase IIb dose finding study.

Speaker: Professor G. Felker (Durham, US)

Discussion: BLAST-AHF.


The clinical value of neutrophil gelatinase-associated lipocalin (NGAL) for acute kidney injury during hospitalization for acute heart failure.

Speaker: Professor A. Maisel (San Diego, US)

Discussion: NGAL.


6 speakers from this session

Professor Karen Sliwa

University of Cape Town, Cape Town (South Africa)
17 presentations
1 follower

Professor John R Teerlink

San Francisco Veterans Affairs Medical Center, San Francisco (United States of America)
18 presentations
0 follower

Professor Veselin Mitrovic

Kerckhoff Clinic, Department of Cardiology, Bad Nauheim (Germany)
4 presentations
0 follower

Professor G Michael Felker

Duke Clinical Research Institute, Durham (United States of America)
11 presentations
0 follower

Professor Alan Maisel

University of California, San Diego, San Diego (United States of America)
17 presentations
0 follower

Doctor Martin Jesus GARCIA

Hospital Universitario de Canarias, S. Cristóbal de La Laguna - Tenerife (Spain)
1 presentation
0 follower

This platform is supported by

logo Novo Nordisk